The Manufacturers Life Insurance Company Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

The Manufacturers Life Insurance Company acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 119,516 shares of the biotechnology company’s stock, valued at approximately $1,195,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BCRX. Bank of America Corp DE increased its stake in shares of BioCryst Pharmaceuticals by 231.6% in the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after buying an additional 3,556,208 shares during the period. Pacer Advisors Inc. acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth approximately $14,880,000. Wedge Capital Management L L P NC bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $3,808,000. Perceptive Advisors LLC increased its position in BioCryst Pharmaceuticals by 135.1% in the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares during the period. Finally, Rice Hall James & Associates LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $23,320,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 1.3%

BCRX opened at $9.96 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The company has a fifty day moving average of $9.75 and a 200-day moving average of $9.17. The stock has a market cap of $2.55 billion, a PE ratio of -6.64 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.15 earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. Wedbush lowered their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Royal Bank Of Canada reduced their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald increased their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.